Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Yehuda Z Cohen"'
Autor:
Henning Gruell, MD, Jesper D Gunst, MD, Yehuda Z Cohen, MD, Marie H Pahus, Jakob J Malin, MD, Martin Platten, MD, Katrina G Millard, RN, Martin Tolstrup, PhD, R Brad Jones, PhD, Winnifer D Conce Alberto, Julio C C Lorenzi, PhD, Thiago Y Oliveira, PhD, Tim Kümmerle, MD, Isabelle Suárez, MD, Cecilia Unson-O'Brien, PhD, Lilian Nogueira, PhD, Rikke Olesen, PhD, Lars Østergaard, ProfMD, Henrik Nielsen, ProfMD, Clara Lehmann, MD, Michel C Nussenzweig, ProfMD, Gerd Fätkenheuer, ProfMD, Florian Klein, ProfMD, Marina Caskey, ProfMD, Ole S Søgaard, ProfMD
Publikováno v:
The Lancet Microbe, Vol 3, Iss 3, Pp e203-e214 (2022)
Summary: Background: The administration of broadly neutralising anti-HIV-1 antibodies before latency reversal could facilitate elimination of HIV-1-infected CD4 T cells. We tested this concept by combining the broadly neutralising antibody 3BNC117 in
Externí odkaz:
https://doaj.org/article/b572a4bc81f74c27b4e7e697acac132e
Autor:
Yehuda Z Cohen, Allison L Butler, Katrina Millard, Maggi Witmer-Pack, Rebeka Levin, Cecilia Unson-O'Brien, Roshni Patel, Irina Shimeliovich, Julio C C Lorenzi, Jill Horowitz, Stephen R Walsh, Shu Lin, Joshua A Weiner, Anna Tse, Alicia Sato, Chelsey Bennett, Bryan Mayer, Kelly E Seaton, Nicole L Yates, Lindsey R Baden, Allan C deCamp, Margaret E Ackerman, Michael S Seaman, Georgia D Tomaras, Michel C Nussenzweig, Marina Caskey
Publikováno v:
PLoS ONE, Vol 14, Iss 8, p e0219142 (2019)
BackgroundAdditional forms of pre-exposure prophylaxis are needed to prevent HIV-1 infection. 3BNC117 and 10-1074 are broadly neutralizing anti-HIV-1 antibodies that target non-overlapping epitopes on the HIV-1 envelope. We investigated the safety, t
Externí odkaz:
https://doaj.org/article/b4f6a55fa3004a4ca5d76ce1d1d48b8b
Autor:
Timothy Chow, Pirouz Shamszad, Christopher Vinnard, Esther Yoon, Julia Belinski, Irene Karpenko, Laurent Perrin, Kristen Auwarter, Michael Storek, Howard Surks, Nancy Wong, Yehuda Z. Cohen
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 4, Pp 673-685 (2023)
Abstract SAR445088 is an anti‐C1s humanized monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system and has the potential to provide clinical benefit in the treatment of complement‐mediated disea
Externí odkaz:
https://doaj.org/article/4c9f0415ae8e411dbf130400568bddf6
Autor:
Cathrine Axfors, Andreas M. Schmitt, Perrine Janiaud, Janneke van’t Hooft, Sherief Abd-Elsalam, Ehab F. Abdo, Benjamin S. Abella, Javed Akram, Ravi K. Amaravadi, Derek C. Angus, Yaseen M. Arabi, Shehnoor Azhar, Lindsey R. Baden, Arthur W. Baker, Leila Belkhir, Thomas Benfield, Marvin A. H. Berrevoets, Cheng-Pin Chen, Tsung-Chia Chen, Shu-Hsing Cheng, Chien-Yu Cheng, Wei-Sheng Chung, Yehuda Z. Cohen, Lisa N. Cowan, Olav Dalgard, Fernando F. de Almeida e Val, Marcus V. G. de Lacerda, Gisely C. de Melo, Lennie Derde, Vincent Dubee, Anissa Elfakir, Anthony C. Gordon, Carmen M. Hernandez-Cardenas, Thomas Hills, Andy I. M. Hoepelman, Yi-Wen Huang, Bruno Igau, Ronghua Jin, Felipe Jurado-Camacho, Khalid S. Khan, Peter G. Kremsner, Benno Kreuels, Cheng-Yu Kuo, Thuy Le, Yi-Chun Lin, Wu-Pu Lin, Tse-Hung Lin, Magnus Nakrem Lyngbakken, Colin McArthur, Bryan J. McVerry, Patricia Meza-Meneses, Wuelton M. Monteiro, Susan C. Morpeth, Ahmad Mourad, Mark J. Mulligan, Srinivas Murthy, Susanna Naggie, Shanti Narayanasamy, Alistair Nichol, Lewis A. Novack, Sean M. O’Brien, Nwora Lance Okeke, Léna Perez, Rogelio Perez-Padilla, Laurent Perrin, Arantxa Remigio-Luna, Norma E. Rivera-Martinez, Frank W. Rockhold, Sebastian Rodriguez-Llamazares, Robert Rolfe, Rossana Rosa, Helge Røsjø, Vanderson S. Sampaio, Todd B. Seto, Muhammad Shahzad, Shaimaa Soliman, Jason E. Stout, Ireri Thirion-Romero, Andrea B. Troxel, Ting-Yu Tseng, Nicholas A. Turner, Robert J. Ulrich, Stephen R. Walsh, Steve A. Webb, Jesper M. Weehuizen, Maria Velinova, Hon-Lai Wong, Rebekah Wrenn, Fernando G. Zampieri, Wu Zhong, David Moher, Steven N. Goodman, John P. A. Ioannidis, Lars G. Hemkens
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-2 (2024)
Externí odkaz:
https://doaj.org/article/eaaad84f79e74e2bbfb5c0c8a4146fc5
Autor:
Henning Gruell, Jesper D Gunst, Yehuda Z Cohen, Marie H Pahus, Jakob J Malin, Martin Platten, Katrina G Millard, Martin Tolstrup, R Brad Jones, Winnifer D Conce Alberto, Julio C C Lorenzi, Thiago Y Oliveira, Tim Kümmerle, Isabelle Suárez, Cecilia Unson-O'Brien, Lilian Nogueira, Rikke Olesen, Lars Østergaard, Henrik Nielsen, Clara Lehmann, Michel C Nussenzweig, Gerd Fätkenheuer, Florian Klein, Marina Caskey, Ole S Søgaard
Publikováno v:
Gruell, H, Gunst, J D, Cohen, Y Z, Pahus, M H, Malin, J J, Platten, M, Millard, K G, Tolstrup, M, Jones, R B, Conce Alberto, W D, Lorenzi, J C C, Oliveira, T Y, Kümmerle, T, Suárez, I, Unson-O'Brien, C, Nogueira, L, Olesen, R, Østergaard, L, Nielsen, H, Lehmann, C, Nussenzweig, M C, Fätkenheuer, G, Klein, F, Caskey, M & Søgaard, O S 2022, ' Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP) : a randomised, open-label, phase 2A trial ', The Lancet Microbe, vol. 3, no. 3, pp. e203-e214 . https://doi.org/10.1016/S2666-5247(21)00239-1
Gruell, H, Gunst, J D, Cohen, Y Z, Pahus, M H, Malin, J J, Platten, M, Millard, K G, Tolstrup, M, Jones, R B, Conce Alberto, W D, Lorenzi, J C C, Oliveira, T Y, Kümmerle, T, Suárez, I, Unson-O'Brien, C, Nogueira, L, Olesen, R, Østergaard, L, Nielsen, H, Lehmann, C, Nussenzweig, M C, Fätkenheuer, G, Klein, F, Caskey, M & Søgaard, O S 2022, ' Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial ', The Lancet. Microbe, vol. 3, no. 3, pp. e203-e214 . https://doi.org/10.1016/S2666-5247(21)00239-1
Lancet Microbe
Gruell, H, Gunst, J D, Cohen, Y Z, Pahus, M H, Malin, J J, Platten, M, Millard, K G, Tolstrup, M, Jones, R B, Conce Alberto, W D, Lorenzi, J C C, Oliveira, T Y, Kümmerle, T, Suárez, I, Unson-O'Brien, C, Nogueira, L, Olesen, R, Østergaard, L, Nielsen, H, Lehmann, C, Nussenzweig, M C, Fätkenheuer, G, Klein, F, Caskey, M & Søgaard, O S 2022, ' Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial ', The Lancet. Microbe, vol. 3, no. 3, pp. e203-e214 . https://doi.org/10.1016/S2666-5247(21)00239-1
Lancet Microbe
Background: The administration of broadly neutralising anti-HIV-1 antibodies before latency reversal could facilitate elimination of HIV-1-infected CD4 T cells. We tested this concept by combining the broadly neutralising antibody 3BNC117 in combinat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4577964d701c8fd239bfcbc60048b209
https://pure.au.dk/portal/da/publications/effect-of-3bnc117-and-romidepsin-on-the-hiv1-reservoir-in-people-taking-suppressive-antiretroviral-therapy-roadmap(7c6928fe-3cc7-425c-8be8-33a09ee7c80c).html
https://pure.au.dk/portal/da/publications/effect-of-3bnc117-and-romidepsin-on-the-hiv1-reservoir-in-people-taking-suppressive-antiretroviral-therapy-roadmap(7c6928fe-3cc7-425c-8be8-33a09ee7c80c).html
Autor:
Amy E. Baxter, Marina Caskey, Pilar Mendoza, Daniel Kaufmann, Ching-Lan Lu, Yehuda Z. Cohen, Mila Jankovic, Julia Niessl, Allison L. Butler, Michel C. Nussenzweig, Florian Klein, Henning Gruell, Mathieu Dubé, Irina Shimeliovich
Publikováno v:
Nature Medicine
Combination antiretroviral therapy (ART) is highly effective in controlling human immunodeficiency virus (HIV)-1 but requires lifelong medication due to the existence of a latent viral reservoir1,2. Potent broadly neutralizing antibodies (bNAbs) repr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5798027c90cd387f920e0b81a6cac8f7
http://europepmc.org/articles/PMC7018622
http://europepmc.org/articles/PMC7018622
Autor:
Yehuda Z. Cohen, Xiaojia Zhang, Binfeng Xia, Matthew P. Kosloski, Mohamed A. Kamal, John D. Davis, Vanaja Kanamaluru, Christine Xu
Publikováno v:
Clinical pharmacology in drug development. 11(5)
Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, has demonstrated efficacy and an acceptable safety profile in adult and pediatric patients with moderate-to-severe atopic dermatitis (AD) and other type 2 inflammatory disea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ee1e853b72646ce6ce95850cfba82a3
https://pubmed.ncbi.nlm.nih.gov/35278283
https://pubmed.ncbi.nlm.nih.gov/35278283
Autor:
Steven N. Goodman, Norma E. Rivera-Martinez, Magnus Nakrem Lyngbakken, David Moher, John P. A. Ioannidis, Frank W. Rockhold, Todd B. Seto, Helge Røsjø, Vincent Dubée, Ahmad Mourad, Andrea B. Troxel, Carmen M. Hernández-Cárdenas, Vanderson de Souza Sampaio, Thuy Le, Andy I. M. Hoepelman, Fernando Val, Sean M. O'Brien, Ting Yu Tseng, Leila Belkhir, Susanna Naggie, Patricia Meza-Meneses, Marvin A.H. Berrevoets, Javed Akram, Alistair Nichol, Léna Perez, Rebekah Wrenn, Susan C. Morpeth, Laurent Perrin, Felipe Jurado-Camacho, Lindsey R. Baden, Shehnoor Azhar, Bryan J. McVerry, Cheng-Yu Kuo, Arantxa Remigio-Luna, Thomas Hills, Cathrine Axfors, Ireri Thirion-Romero, Steve Webb, Wuelton Marcelo Monteiro, Jason E. Stout, Jesper M. Weehuizen, Peter G. Kremsner, Shanti Narayanasamy, Derek C. Angus, Yehuda Z. Cohen, Shu Hsing Cheng, Gisely Cardoso de Melo, Rossana Rosa, Nwora Lance Okeke, Stephen R. Walsh, Srinivas Murthy, Anissa Elfakir, Mark J. Mulligan, Olav Dalgard, Cheng-Pin Chen, Tse Hung Lin, Fernando G. Zampieri, Khalid S. Khan, Yi-Wen Huang, Anthony C. Gordon, Yaseen M. Arabi, Wu Zhong, Hon Lai Wong, Wei Sheng Chung, Bruno Igau, Andreas M. Schmitt, Maria Velinova, Robert J. Ulrich, Nicholas A Turner, Wu Pu Lin, Janneke van’t Hooft, Shaimaa Soliman, Lennie P. G. Derde, Colin McArthur, Arthur W. Baker, Benno Kreuels, Ravi K. Amaravadi, Ronghua Jin, Benjamin S. Abella, Sherief Abd-Elsalam, Thomas Benfield, Lewis A. Novack, Lars G. Hemkens, Ehab F. Abdo, Perrine Janiaud, Sebastian Rodriguez-Llamazares, Chien Yu Cheng, Muhammad Shahzad, Robert Rolfe, Tsung Chia Chen, Yi-Chun Lin, Rogelio Perez-Padilla, Marcus V. G. Lacerda, Lisa N. Cowan
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-2 (2021)
Nature Communications
Nature Communications
Substantial COVID-19 research investment has been allocated to randomized clinical trials (RCTs) on hydroxychloroquine/chloroquine, which currently face recruitment challenges or early discontinuation. We aim to estimate the effects of hydroxychloroq
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd12e44c7dfe0fbf267480cac84e1c96
http://hdl.handle.net/10044/1/89425
http://hdl.handle.net/10044/1/89425
Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Primary African Isolates
Autor:
Michel C. Nussenzweig, Julio C. C. Lorenzi, Connie Celum, Marie Wiatr, Joseph Sapiente, Sinead Delany, Lilian Nogueira, Michael S. Seaman, Marina Caskey, Yehuda Z. Cohen, Christy L. Lavine, Jairam R. Lingappa, Andrew Mujugira, Pilar Mendoza, Nelly Mugo
Publikováno v:
Journal of Virology
HIV remains a major public health problem worldwide, and new therapies and preventive strategies are necessary for controlling the epidemic. Broadly neutralizing antibodies (bNAbs) have been developed in the past decade to fill this gap.
Novel t
Novel t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1431487c712db2e3e781d58b35dc046
https://doi.org/10.1128/jvi.01909-20
https://doi.org/10.1128/jvi.01909-20
Autor:
Robert F. Siliciano, Weimin Liu, Alexa N. Avitto, Michel C. Nussenzweig, Yehuda Z. Cohen, Paul M. Sharp, Michael S. Saag, Ronnie M. Russell, Luis J. Montaner, Frederic Bibollet-Ruche, Ronald G. Collman, George M. Shaw, Pierre Pellegrino, Sonya L. Heath, Julio C. C. Lorenzi, Jesse Connell, Ian Williams, Stephanie Trimboli, Andrew G. Smith, M. Alexandra Monroy, Scott Sherrill-Mix, Yingying Li, Beatrice H. Hahn, Janet M. Siliciano, D. Brenda Salantes, Lindsey J. Plenderleith, Emmanouil Papasavvas, Angharad E. Fenton-May, Julia DeVoto, Katharine J. Bar, Marina Caskey, Marcos V. P. Gondim, Persephone Borrow, Felicity Mampe
Publikováno v:
Gondim, M V P, Sherrill-Mix, S, Bibollet-Ruche, F, Russell, R M, Trimboli, S, Smith, A G, Li, Y, Liu, W, Avitto, A N, DeVoto, J C, Connell, J, Fenton-May, A E, Pellegrino, P, Williams, I, Papasavvas, E, Lorenzi, J C C, Brenda Salantes, D, Mampe, F, Alexandra Monroy, M, Cohen, Y Z, Heath, S, Saag, M S, Montaner, L J, Collman, R G, Siliciano, J M, Siliciano, R F, Plenderleith, L J, Sharp, P M, Caskey, M, Nussenzweig, M C, Shaw, G M, Borrow, P, Bar, K J & Hahn, B H 2021, ' Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption ', Science Translational Medicine, vol. 13, no. 576, eabd8179 . https://doi.org/10.1126/SCITRANSLMED.ABD8179
Sci Transl Med
Sci Transl Med
Type 1 interferons (IFN-I) are potent innate antiviral effectors that constrain HIV-1 transmission. However, harnessing these cytokines for HIV-1 cure strategies has been hampered by an incomplete understanding of their antiviral activities at later
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd61e6b06a1340de5cdaf3c9a30f3230
https://hdl.handle.net/20.500.11820/a6051f01-6cf5-434d-b22c-8486e3fd60c2
https://hdl.handle.net/20.500.11820/a6051f01-6cf5-434d-b22c-8486e3fd60c2